Figure 4 displays a forest plot of the risk ratio (RR) of flare in the randomized discontinuation trials of certain biologic DMARDs (abatacept, adalimumab, anakinra, etanercept, IVIG, and tocilizumab). Overall, the RR for having a flare among those who continued compared to those who discontinued was 0.48 (95 percent CI 0.36 to 0.63) over 4 months to 2 years. Although there is heterogeneity in study design, the RR for having a flare was similar across all studies (chi-squared = 3.18, df = 3, p = 0.36; I-squared = 6 percent).

Figure 4Comparison of symptomatic flares in children with JIA randomized to continuing a biologic DMARD versus placebo

Flares are listed as “Events” in the figure.

From: Results

Cover of Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA)
Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) [Internet].
Comparative Effectiveness Reviews, No. 28.
Kemper AR, Coeytaux R, Sanders GD, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.